Patient co-payments and use of prescription medicines

Australian and New Zealand Journal of Public Health

Volumn 28, Issue 1, 2004, Pages 62-67

  Doran, Evan ^a   Robertson, Jane ^a   Rolfe, Isobel ^a   Henry, David ^a  

^a UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; DRUG;

ADULT; AGED; ARTICLE; AUSTRALIA; CHI SQUARE TEST; CHILD; COMMUNITY; CONFIDENCE INTERVAL; CONSULTATION; CONTROLLED STUDY; DRUG COST; DRUG DOSE REDUCTION; DRUG USE; FEMALE; GENERAL PRACTICE; GENERAL PRACTITIONER; HEALTH CARE COST; HOUSEHOLD; HUMAN; HYPERTENSION; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MEDICAL FEE; PATIENT ATTITUDE; PHYSICAL DISEASE; PRESCRIPTION; QUALITATIVE ANALYSIS; SAFETY; SIDE EFFECT; STATISTICS;

EID: 1342305417     PISSN: 13260200     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1467-842X.2004.tb00634.x     Document Type: Article

References (39)

1. The Treasury. 2001 Budget Paper No. 1 - Budget Strategy and Outlook. Statement No.6 Expenses and Net Capital Investment, Part1. Canberra (ACT): Commonwealth Government of Australia; 2001.
2. Sansom L. The Australian National Drug Policy. J Qual Clin Pract 1999;19;31-5.
3. Goddard M, Henry DA, Birkett D. Securing the future of the pharmaceutical benefits scheme. In: Mooney G, Plant A, editors. Daring to Dream: The Future of Australian Health Care. (Author Place of publication????) Black Swan Press; 2001.
4. Rickard M. The Pharmaceutical Benefits Scheme: Options for Cost Control. Canberra (ACT): Department of the Parliamentary Library, Commonwealth of Australia; 2002. Current Issues Brief No.: 12, 2001-02.
5. Davey P, Lees M, Aristides M. Report on the Australian System of Pharmaceutical Financing and Delivery. Vol 1. Efficiency and equity implications of public versus private funding of pharmaceuticals. Chatswood (NSW): Medical Technology Assessment Group; 1999.
6. Salkeld G, Mitchell A, Hill SR. Pharmaceuticals. In: Mooney G, Scotton R, editors. Economics and Australian Health Policy. Sydney (NSW): Allen and Unwin; 1999. p. 115-136.
7. McAuley I. Direct payments for health care. Healthcover 1999;8:58-63.
8. Peabody J, Bickel SR, Lawson J. The Australian health care system: Are the incentives down under right side up? J Am Med Assoc 1996;276:1944-50.
9. Keeler EB, Rolph JE. How cost sharing reduced medical spending of participants in the health insurance experiment. J Am Med Assoc 1983;249:2220-7.
10. Nelson AA Jr, Reeder CE, Dickson WM. The effect of a Medicaid drug copayment program on the utilisation and cost of prescription services. Med Care 1984;22:724-736.
11. Richardson J. Evidenced based policy: Can we move on? Healthcover 1999; April-May, 39-41.
12. Commonwealth Department of Health and Ageing. The National Strategy for Quality Use of Medicines. Canberra (ACT): Commonwealth of Australia; 2002.
13. Mechanic D, Rochefort DA. Comparative medical systems. Ann Rev Sociol 1996;22:239-70.
14. Gedtham U-G, Johannesson M. The impact of user charges on the consumption of drugs. Pharmacoeconomics 1996;9:478-83.
15. Mooney G. Key Issues in Health Economics. Hempstead (UK): Prentice Hall; 1992.
16. Stuart B, Grana J. Ability to pay and the decision to medicate. Med Care 1998;36:202-11.
17. Liebowitz A, Manning WG, Newhouse JP. The demand for prescription drugs as a function of cost sharing. Soc Sci Med 1985;21:1063-9.
18. Liebowitz A. Substitution between prescribed and over the counter medications. Med Care 1989;27:85-94.
19. Johnson RE, Goodman MJ, Hornbrook MC, Eldridge MB. The effect of increased prescription drug cost-sharing on medical care utilisation and expenses of elderly health organisation members. Med Care 1997;35:1119-31.
20. Martin BC, McMillan JA. The impact of implementing a more restrictive prescription limit on Medicaid recipients: Effects on cost, therapy and out-of-pocket expenditures. Med Care 1996;34:686-701.
21. Soumerai SB, Avorn J, Ross-Degnan D, Gortmaker S. Payment restrictions for prescription drugs under Medicaid. Effects on cost, therapy and equity. N Engl J Med 1987;317:550-6.
22. Soumerai SB, Avorn J, McLaughlin T, Choodnovskiy I. Effects of Medicaid drug-payment limits on admission to hospitals and nursing homes. N Engl J Med 1991;325:1072-7.
23. Soumerai SB, McLaughlin TJ, Ross-Degnan D, Casteris CS, Bollini P. Effects of a limit on Medicaid drug-reimbursement on the use of psychotropic agents and acute mental health services by patients with schizophrenia. N Engl J Med 1994;331:650-5.
24. Freemantle N, Bloor K. Lessons from international experience in controlling pharmaceutical expenditure. 1: Influencing patients. Br Med J 1996;312:1469-71.
25. Lexchin J, Grootendorst P. The Effects of Prescription Drug User Fees on Drug and Health Services Use and Health Status: A Review of the Evidence. Personnel communication 2002.
26. Harvey DR, Tatchell PM. The Effects of Variations in Patient Contributions, Income and Doctor Supply on the Demand for PBS Drugs. Canberra (ACT): Health Economics Research Unit, Australian National University; 1984. p. 25-57.
27. Johnston M. Price elasticity of demand for pharmaceuticals. In: Selby-Smith C, editor Economics and Health. Melbourne (VIC): Public Sector Management Institute and National Centre for Health Program Evaluation, Monash University; 1991.
28. McManus P, Donnelly N, Henry D, Hall W, Primrose J, Lindner J. Prescription drug utilization following patient co-payment changes in Australia. Pharmacoepidemiol Drug Saf 1996;5:385-92.
29. Consumer's Health Forum. Costs of Chronic Illness and Quality Use of Medicines. Canberra(ACT): Consumer's Health Forum of Australia; 1997.
30. Walker A. Distributional Impact of Higher Patient Contributions on Australia's Pharmaceutical Benefits Scheme. Discussion Paper 45. Canberra (ACT): National Centre for Social and Economic Modelling, University of Canberra; 1999.
31. Chubon SJ, Schulz RM, Lingle EW, Coster-Schulz MA. Too many medications, too little money: How do patients cope? Public Health Nurs 1994;11:412-15.
32. Strickland WJ, Hanson CM. Coping with the cost of prescription drugs. J Health Care Poor Underserved 1996;7:50-62.
33. SPSS; Statistical Package for the Social Sciences [Computer Program]. Version 10.0. Chicago (Ill): SPSS; 1999.
34. Strauss A, Corbin J. Basics of Qualitative Research: Techniques and Procedures for Developing Grounded Theory. Thousands Oaks (CA): Sage Publications; 1991.
35. Berg BL. Qualitative Research Methods for the Social Sciences. Boston (MA): Allyn and Bacon; 1989.
36. Mays N, Pope C. Assessing quality in qualitative research. Br Med J 2000;320:50-2.
37. Blendon RJ, Schoen C, et al. Inequities in healthcare: A five country survey. Health Affairs 2002;21(3):182-191.
38. Schafheutle EL, Hassell K, Noyce PR, Weiss MC. Access to medicines: Cost as an influence on the views and behaviours of patients. Health Soc Care Community 2002; 10:187-95.
39. Consumers Health Forum. Understanding Consumer Behaviour and Experiences in Relation to the Use of Medicine: A Literature Review. Canberra (ACT): Consumer's Health Forum at Australia; 1999.